COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Exhibition of entries for 6th China animal specimen competition opens in Shanghai
- Steam train ice sculpture wows Harbin ice festival
- Xi congratulates Jose Antonio Kast on election as Chilean president
- Draft law enhances polar activities, security in Antarctica
- International students celebrate New Year in Shanxi gala
- China mulls Trademark Law amendment to build world-class business environment
